Almirall (FRA:E2Z) Common Stock : €0.0 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Almirall Common Stock?

Almirall's quarterly common stock stayed the same from Jun. 2023 (€25.1 Mil) to Dec. 2023 (€25.1 Mil) but then declined from Dec. 2023 (€25.1 Mil) to Mar. 2024 (€0.0 Mil).

Almirall's annual common stock increased from Dec. 2021 (€21.6 Mil) to Dec. 2022 (€21.8 Mil) and increased from Dec. 2022 (€21.8 Mil) to Dec. 2023 (€25.1 Mil).

Almirall Common Stock Historical Data

The historical data trend for Almirall's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall Common Stock Chart

Almirall Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

20.95

21.37

21.57

21.78

25.13

Almirall Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															21.78	-	25.13	25.13	-

Almirall Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Almirall (FRA:E2Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (FRA:E2Z) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

LBTSF:USA 0O9B:UK ALM:Spain E2Z:Germany

Address

Ronda General Mitre 151, Barcelona, ESP, 08022

Website

http://www.almirall.es

Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall (FRA:E2Z) Headlines

No Headlines